Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zolodine refers to capsules containing ziprasidone hydrochloride, an atypical antipsychotic medication. Its therapeutic effects are primarily mediated through a combination of antagonism at dopamine D2 and serotonin 5HT2A receptors. Additionally, it acts as an agonist at serotonin 5HT1A receptors and an antagonist at serotonin 5HT1D, 5HT2C, alpha-1 adrenergic, and histamine H1 receptors. It also exhibits modest inhibition of norepinephrine and serotonin reuptake. Ziprasidone hydrochloride is approved for the treatment of schizophrenia, bipolar mania, and acute agitation in individuals with schizophrenia, as well as for manic or mixed episodes and maintenance treatment of bipolar I disorder. [1, 2, 3, 4, 5, 11]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zolodine.